Objective: The Flow Cytometry Shared Resource (FCSR) supports translational and clinical cancer research projects of University of Colorado Cancer Center (UCCC) members with flow cytometric analysis, high-speed cell sorting, microscopy, and multiplexed fluorescent microsphere assays. Services and Technologies: FCSR provides a wide range of assays particulariy pertinent to cancer research, including cell cycle, cell proliferation, apoptosis, cell viability, cell signaling, stem cell detection, fluorescent protein analysis, and cell phenotyping along with cell sorting. Housing 4 high-speed sorters, 8 color analyzers, 1 Luminex system, 1 cell counter, 1 imaging cytometer, 6 microscopes, and 1 confocal scanning system, FCSR has 5,000 and 13,500 hours/year of cell sorting and analysis capacity, respectively;1,500 hours/year of Luminex capacity;and 12,000 hours/year of microscope-based research capacity. Consultation and Training: FCSR provides a consultation to help those members with little flow cytometry or immunology background to design appropriate experiments. In addition, regular training sessions are held to inform UCCC members and the investigators in their laboratories of new techniques and FCSR capabilities. Many investigators also call FCSR on an ad hoc basis for advice on performing experiments. Utilization: FCSR is among the most popular and most highly used of the UCCC shared resources. More than 100 different Cancer Center members from 6 programs and 7 consortium institutions use either the UCD or the NJH branch facilities. Management and Finances: This resource is UCCC-managed. Currently, 7 1% of the operating budget comes from charge backs to UCCC members who represent 76% of Shared Resource users. FCSR requests $220,370 CCSG support for 2 1% of its operating budget Increased funding will expand assay capabilities and will maintain the FCSR's place at the forefront of cytometry technology as the first Beckman Coulter Cytometry Center of Excellence.

Public Health Relevance

Using flow cytometric analysis, high-speed cell sorting, microscopy, and multiplexed fluorescent microsphere assays, the Flow Cytometry Shared Resource can perform a wide range of assays supporting cancer research, including cell cycle, cell proliferation, apoptosis, cell viability, cell signaling, stem cell detection, fluorescent protein analysis, and cell phenotyping. These assays are crucial to understanding how cancer derails normal cellular processes to cause disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616655
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$51,756
Indirect Cost
$19,136
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications